GM-CSF Monoclonal Antibody (3092), Invitrogen™

Description

M500A targets Human GM-CSF in ELISA, and WB applications and shows reactivity with Human samples. The M500A immunogen is glycosylated, CHO-derived recombinant human GM-CSF. M500A detects Human GM-CSF which has a predicted molecular weight of approximately 14 kDa. The M500A GMCSF antibody (clone 3092) has successfully been paired as the coating antibody in a sandwich ELISA with detection antibody M501B (biotinylated conjugate of clone 1089). Typical dilutions for sandwich ELISA include 1 μg/mL for coating and 0.125 - 0.25 μg/mL for detection. Antibody M500A (clone 3092) and biotinylated antibody M501B (clone 1089) have successfully been used in combination with recombinant GMCSF protein SGMCSF in ELISA applications. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

The GM-CSF gene encodes for a cytokine that regulates the production, differentiation, and function of macrophages and granulocytes. The active form of the protein exists as a homodimer in the extracellular space. This gene is located in a cluster of related genes at the chromosome region 5q31, which has been associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include interleukins 4, 5, and 13. The gene is involved in promoting tissue inflammation. Elevated levels of cytokines, including the one produced by this gene, have been observed in SARS-CoV-2 infected patients with acute respiratory distress syndrome. Mice that lack this gene or its receptor have been shown to develop pulmonary alveolar proteinosis.